FOXO1 and lymphoma: FOXO1 is consistent with other work showing that mutations in this gene are associated with decreased overall survival in DLBCL patients.31CIITA, previously shown to be a recurrent gene fusion partner in lymphoid cancers,32 is a master regulator of MHC class II expression and loss of its function may contribute to escape from immunosurveillance and poor outcome.